Passionate about Progress
We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.
Haduvio™ is an oral, extended-release formulation of nalbuphine. The approved injectable formulation has a long history of efficacy and safety, having been approved for more than 40 years in the United States and Europe for relief of moderate to severe pain in the hospital setting. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.
Nalbuphine has a dual mechanism of action, acting as both an antagonist (blocker) to the body’s mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Nalbuphine’s mechanism of action may also mitigate the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. The injectable form of nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe.
We are developing the investigational therapy Haduvio™ for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal Phase 2b/3 clinical trial of Haduvio™ (PRISM) is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). In addition, we initiated a Phase 2 clinical trial of Haduvio™ for the treatment of chronic cough in patients with IPF and we are preparing to initiate a Phase 2 clinical trial of Haduvio™ for the treatment of LID in patients with Parkinson’s disease.
Board of Directors
David Meeker, M.D. – Chairman
James Cassella, Ph.D.
James Cassella, Ph.D. has served as a member of our board of directors since February 2020. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc., a publicly-traded biotechnology company, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.
Co-Founder, President and CEO
Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Ms. Good currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Ms. Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter and is a Co-Chair of the New Haven Regional Bioscience Collaborative. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
Chief Financial Officer
Lisa Delfini has served as our Chief Financial Officer since August 2021. Ms. Delfini joins Trevi with 30 years of experience in the financial sector. Her background includes helping public and private companies with finance transformation and preparing for and executing capital raising activities, acquisitions, and other complex financial and accounting matters. As a Financial Accounting and Advisory Services Partner at Marcum LLP, Ms. Delfini led a team of professionals who provided advisory services on financial activities to companies. In this role, she served as interim CFO, CAO or controller for companies in multiple sectors, including pharmaceuticals. Previously, Ms. Delfini worked at General Electric where she was the Global Controller for the GE Corporate Technical Center of Excellence (TCOE) and then became the Global Controller for GE Industrial Solutions. Ms. Delfini began her career at Deloitte & Touche LLP where she worked for 16 years and completed her time there as a Client Service Partner. She holds a B.S. in Accounting from Lehigh University and is a Certified Public Accountant in the State of Connecticut.
Thomas Sciascia, M.D.
Co-Founder, Chief Medical Officer
Thomas Sciascia, M.D. is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. Previously, Dr. Sciascia was the Senior Vice President of Clinical Developmentand Regulatory and Chief Medical Officer at Penwest. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.
William Forbes, Pharm.D.
Chief Development Officer
William Forbes, Pharm.D. has served as our Chief Development Officer since February 2021. Dr. Forbes joins Trevi with over 30 years of experience in pharmaceutical product development. Before joining Trevi, he served as Founder, President and CEO of Vivelix Pharmaceuticals. Prior to Vivelix, Dr. Forbes held multiple senior leadership positions throughout his career, including Chief Development Officer for Salix Pharmaceuticals where he was responsible for the development of Xifaxan (rifaximin) in multiple indications. Dr. Forbes’ contributions at Salix were instrumental in guiding 12 FDA approvals. He holds a Pharm.D. from Creighton University.